<DOC>
	<DOCNO>NCT01537692</DOCNO>
	<brief_summary>The purpose study compare systemic level beclomethasone 17 monopropionate ( 17 BMP - active metabolite BDP ) intranasal administration BDP HFA systemic level 17 BMP administration orally inhale BDP HFA healthy volunteer .</brief_summary>
	<brief_title>Clinical Study Evaluate Pharmacokinetics Safety BDP HFA Nasal Aerosol</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Informed Consent Male female subject 1845 year age General good health History physical finding nasal pathology ( within 60 day prior Screening Visit ) Participation investigational drug study 30 day precede Screening Visit History respiratory infection/disorder 28 day precede Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>